CORE B (Biostatistics) The Biostatistics Core (Core B) seeks to assure that all CRC investigators have access to state-of-the-art biostatistical support for all aspects of the design and conduct of their investigations.
Specific Aim 1 : To provide collaborative statistical support for investigations conducted by the members of the CLL Research Consortium (CRC) 1.1 To provide statistical support for the clinical research studies conducted by the CRC. 1.2 To provide statistical support for the laboratory studies conducted by the CRC, including both freestanding studies within the Projects and laboratory correlative studies embedded in the clinical trials. 1.3 To provide statistical support for murine studies conducted by the Projects.
Specific Aim 2 : To participate in the quality assurance and quality improvement processes for the CRC database 2.1 To participate in an ongoing process of quality improvement for the CRC database. 2.2 To advise on quality assurance as new types of data are incorporated into the CRC database.
Specific Aim 3; To participate in the scientific advisory committees of the CRC 3.1 To participate in teleconferences and meetings held by the Clinical Advisory Committee, the Scientific Advisory Committee, and the Data Safety and Monitoring Board. 3.2 To participate in the review of all sample requests submitted to the Tissue Core (Core C).
Specific Aim 4 : To provide a forum for statisticians working in CLL 4.1 To provide, through the distributed Biostatistics Core, a forum for statisticians working in CLL to improve their understanding of the disease and thereby provide even better statistical support to the Projects.
This Core facilitates research designed to translate the findings of basic science into information useful in the clinical arena for CLL patients. It provides a national resource consisting of a dataset of matched samples with corresponding pathological and clinical data. This interactive information on each CLL sample allows for a better understanding of the biology of CLL and improved prognosis and clinical trials for this leukemia.
|Mani, R; Mao, Y; Frissora, F W et al. (2015) Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia 29:346-55|
|Veronese, A; Pepe, F; Chiacchia, J et al. (2015) Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia 29:86-95|
|Woyach, Jennifer A; Furman, Richard R; Liu, Ta-Ming et al. (2014) Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 370:2286-94|
|Chen, Wenbing; Han, Yanyan; Peng, Xiaohua (2014) Aromatic nitrogen mustard-based prodrugs: activity, selectivity, and the mechanism of DNA cross-linking. Chemistry 20:7410-8|
|Stephens, D M; Ruppert, A S; Jones, J A et al. (2014) Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia 28:1365-8|
|Cheney, Carolyn M; Stephens, Deborah M; Mo, Xiaokui et al. (2014) Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs 6:749-55|
|Strati, Paolo; Ferrajoli, Alessandra; Lerner, Susan et al. (2014) Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leuk Lymphoma 55:828-33|
|Cui, Bing; Chen, Liguang; Zhang, Suping et al. (2014) MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood 124:546-54|
|Riches, John C; Gribben, John G (2014) Hanging tough: CMV-specific CD8+ T cells in CLL. Blood 123:608-9|
|Fecteau, Jessie-F; Corral, Laura G; Ghia, Emanuela M et al. (2014) Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood 124:1637-44|
Showing the most recent 10 out of 227 publications